Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.37 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 3/20 | 0.35 |
| ▸ | BMP1 | P13497 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.34 |
| ▸ | PTGIS | Q16647 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3516047 | 0.85 | CYP11B1 (0.41) | HDAC3HDAC6PTGS1PTGS2CYP11B1 | |
| SCHEMBL9239487 | 0.84 | CYP11B1 (0.37) | HDAC3HDAC6PTGS2CYP11B1CYP11B2 | |
| SCHEMBL1765841 | 0.82 | CYP11B1 (0.40) | HDAC3HDAC6PTGS2CYP11B1CYP11B2 | |
| SCHEMBL9233637 | 0.79 | HDAC3 (0.38) | HDAC3HDAC6PTGS1PTGS2CYP11B1 | |
| SCHEMBL8481796 | 0.79 | CYP11B1 (0.40) | HDAC3HDAC6PTGS2CYP11B1CYP11B2 | |
| SCHEMBL28365560 | 0.79 | TBXAS1 (0.41) | HDAC3HDAC6CYP11B1CYP11B2NOS1 | |
| SCHEMBL4957722 | 0.79 | NOS1 (0.47) | PTGS1NOS1BMP1 | |
| SCHEMBL5643534 | 0.79 | NOS1 (0.47) | PTGS1NOS1BMP1 | |
| SCHEMBL9235495 | 0.78 | CYP11B1 (0.37) | HDAC3HDAC6PTGS2CYP11B1CYP11B2 | |
| SCHEMBL28067941 | 0.78 | CYP11B1 (0.42) | HDAC3HDAC6PTGS2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1481975-A1 | Inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| EP-0892797-A4 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030216441-A1 | Farnesyltransferase inhibitors | WEINSTOCK, STEVEN F. | 2003-11-20 | — | — | US | disclosed |
| US-6455523-B1 | ADMINISTERING 1,4-BENZODIAZEPINE DERIVATIVE AS ANTITUMOR OR ANTICARCINOGENIC AGENT | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-6011029-A | BENZODIAZEPINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-01-04 | — | — | US | disclosed |
| EP-0892797-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997030992-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216441-A1 | Farnesyltransferase inhibitors | FNTA, FNTB, LCAT | HDAC3 1462/4885HDAC6 647/4885PTGS1 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.